GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
- Conditions
- Cystic FibrosisMucociliary Clearance
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01025713
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
- Conditions
- Cystic FibrosisMucociliary ClearanceAirway Hydration
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00999531
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
- Conditions
- Cystic FibrosisPseudomonas Aeruginosa
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00989807
- Locations
- 🇨🇦
University of Calgary, Adult CF Clinic, Calgary, Alberta, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
- Conditions
- Cystic FibrosisAirway HydrationMucociliary Clearance
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT00951522
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: FTC/TDF
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00936715
Stress Echocardiography Study With Regadenoson
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT00907764
- Locations
- 🇬🇧
Northwick Park Hospital, Harrow, United Kingdom
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00892437
- Locations
- 🇺🇸
Health for Life Clinic, PLLC, Little Rock, Arkansas, United States
🇺🇸Therapeutic Concepts, P.A., Houston, Texas, United States
🇺🇸AIDS Healthcare Foundation-Research Center, Beverly Hills, California, United States
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary FibrosisPulmonary Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT00879229
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇦🇹Medizinische Universität Graz, Graz, Austria
🇦🇹Universitatsklinikum Innsbruck, Innsbruck, Austria
Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 307
- Registration Number
- NCT00874796
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT00869557
- Locations
- 🇺🇸
Northstar Medical Center, Chicago, Illinois, United States
🇺🇸Southampton Healthcare, Inc., St. Louis, Missouri, United States
🇺🇸Gordon E. Crofoot, MD, PA, Houston, Texas, United States